Skip to main content

Table 3 Multivariate analysis of PFS on pretreatment quality of life of QLQ-C30 among 501 patients with nasopharyngeal carcinoma

From: Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT

 

HR

95%CI

P

Age

1.200

0.692–2.079

0.516

Gender

0.772

0.395–1.510

0.450

Marriage

1.470

0.458–4.719

0.517

Education

1.197

0.940–1.525

0.145

Smoking history

0.951

0.518–1.747

0.872

Alcohol history

0.787

0.324–1.910

0.596

T stage

1.383

0.684–2.794

0.367

N stage

1.979

1.156–3.388

0.013

Pre-treatment EBV DNA

1.451

0.866–2.431

0.157

Post-treatment EBV DNA

3.130

1.563–6.267

0.001

Pain

1.015

0.995–1.035

0.146

Teeth

0.984

0.971–0.998

0.026

Felt ill

1.004

1.001–1.007

0.012

  1. Abbreviations: PFS Progression free survival, HR Harsard ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us